title: Long-term evolution of renal function in patients with ovarian cancer after whole abdominal irradiation with or without preceding cisplatin.
abstract: BACKGROUND
  The upper limit of the natural decline in creatinine clearance is 1 ml/min/year. To define the loss of renal function, we started a long-term assessment of patients with ovarian cancer treated by whole abdominal irradiation (WAI) with preceding cisplatin chemotherapy (CDDP) and second-look laparotomy (SLL).
  
  
  METHODS
  We analyzed the creatinine clearance over time of 56 patients treated from 1982 to 1988 for ovarian cancer. Thirty-one of 56 patients had received WAI after their initial surgery, and 25 of 56 patients had undergone CDDP therapy followed by SLL, and then WAI after their initial surgery. Median follow-up was 99 months (7-156). Twenty of 56 patients accepted our invitation for additional assessment of tubular function, nine of the 31 patients without CDDP therapy and SLL, and 11 of the 25 patients with CDDP followed by SLL and WAI. Ten of twenty patients had received four to six cycles CDDP, 80 mg/m2/cycle, and one patient nine cycles. The median total dose for each kidney was 1450 cGy (480-1690).
  
  
  RESULTS
  The mean creatinine clearance decreased from 84 ml/min to 66 ml/min. Seventy-six percent of the 25 patients who had undergone CDDP therapy, SLL and WAI had declines of more than 1 ml/min/year, 64% of these patients of more than 2 ml/min/year. For the 31 patients who had received WAI after their initial surgery, the corresponding numbers were 71% and 55%, respectively. The tubular function of the 20 patients who had undergone the additional investigations was not impaired.
  
  
  CONCLUSIONS
  The decline in renal function after WAI is more pronounced than in healthy subjects. The treatment with cisplatin and SLL prior to WAI does not seem to contribute to this loss of kidney function.
authors.affiliation: Department of Radiation Oncology, University of Bern, Inselspital, Switzerland.
authors.forename: D P
authors.initials: DP
authors.lastname: Schneider
authors.forename: H P
authors.initials: HP
authors.lastname: Marti
authors.forename: C
authors.initials: C
authors.lastname: Von Briel
authors.forename: F J
authors.initials: FJ
authors.lastname: Frey
authors.forename: R H
authors.initials: RH
authors.lastname: Greiner
mesh_terms: D000005:Abdomen / Q000528:radiation effects; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003404:Creatinine / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000503:physiopathology* / Q000528:radiation effects; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000503:physiopathology / Q000532:radiotherapy*; D011878:Radiotherapy / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D003404:Creatinine; D002945:Cisplatin